2006
Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer
WILEY A, KATSAROS D, FRACCHIOLI S, YU H. Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210-218. PMID: 16445635, DOI: 10.1111/j.1525-1438.2006.00299.x.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsy, NeedleCarcinomaCohort StudiesDNA MethylationFemaleHumansImmunohistochemistryInsulin-Like Growth Factor Binding Protein 3Multivariate AnalysisNeoplasm StagingOvarian NeoplasmsOvariectomyProbabilityPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSensitivity and SpecificitySurvival RateConceptsIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic marker
2005
A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Positive Breast Cancer
McClusky D, Chu Q, Yu H, DeBenedetti A, Johnson L, Meschonat C, Turnage R, McDonald J, Abreo F, Li B. A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Positive Breast Cancer. Annals Of Surgery 2005, 123: 278-286. PMID: 16192819, PMCID: PMC1402342, DOI: 10.1097/01.sla.0000184224.55949.90.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBlotting, WesternBreast NeoplasmsElectrophoresis, Polyacrylamide GelEukaryotic Initiation Factor-4EFemaleFollow-Up StudiesHumansIncidenceLymph NodesLymphatic MetastasisMastectomy, Extended RadicalMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingProspective StudiesRisk FactorsSurvival RateConceptsNode-positive breast cancerBreast cancerCancer recurrenceHighest tertileEIF4E overexpressionProspective trialNodal statusHigher cancer recurrence rateCancer-related death rateCox proportional hazards modelNode-positive diseaseKaplan-Meier methodCancer recurrence rateLog-rank testCancer-related deathProportional hazards modelRelative risk increaseHigh eIF4E overexpressionRelative risk calculationsMedian followDisease recurrenceIndependent predictorsIntermediate tertileNoncancer patientsProspective study
1999
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
Yu H, Levesque M, Clark G, Diamandis E. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. British Journal Of Cancer 1999, 81: 490-495. PMID: 10507775, PMCID: PMC2362935, DOI: 10.1038/sj.bjc.6690720.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBiomarkers, TumorBreast NeoplasmsCarcinomaChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDNA ReplicationEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenes, p53HumansLife TablesLymphatic MetastasisMastectomyMultivariate AnalysisNeoplasm ProteinsNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPloidiesPrognosisProportional Hazards ModelsProstate-Specific AntigenRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneRiskSensitivity and SpecificitySurvival AnalysisSurvival RateTreatment OutcomeTumor Suppressor Protein p53ConceptsEnzyme-linked immunosorbent assayDisease-free survivalBreast cancer patientsCancer patientsRelative riskCox proportional hazards regression analysisProstate-specific antigen expressionProportional hazards regression analysisReceipt of chemotherapyProgesterone receptor statusSteroid hormone receptor analysisHazards regression analysisRecent clinical evidenceLog-rank testKaplan-Meier plotsOverall survival probabilityHormone receptor analysisPrimary breast carcinomaQuantitative enzyme-linked immunosorbent assayProstate-specific antigenP53 expression statusAssessment of p53Breast cancer prognosisS-phase fractionExpression of p53
1996
Circulating antibodies against p53 protein in patients with ovarian carcinoma
Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis E. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer 1996, 78: 2146-2152. PMID: 8918407, DOI: 10.1002/(sici)1097-0142(19961115)78:10<2146::aid-cncr15>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsOvarian carcinomaP53 antibodiesP53 autoantibodiesPositive patientsSuch antibodiesMultivariate analysisPatient disease-free survivalKaplan-Meier survival curvesSerum p53 antibodiesTumor p53 overexpressionDisease-free survivalOlder patient ageSubset of patientsTumor histologic typeOverall patient survivalSera of patientsFrequent molecular eventUnits/LFree survivalNegative patientsOverall survivalPatient ageSuch autoantibodiesAntibody levels